ClinicalTrials.Veeva

Menu

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Astellas logo

Astellas

Status

Completed

Conditions

Metastatic Hormone-Sensitive Prostate Cancer

Treatments

Other: No Intervention

Study type

Observational

Funder types

Industry

Identifiers

NCT06452212
9785-MA-3541

Details and patient eligibility

About

The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. There are no secondary objectives for this study.

Full description

Data collection for this study will be conducted through 2 rounds of web-based surveys of health care professionals (HCPs). A meeting with the panelists will be held as a 3rd round if a consensus for pre determined key questions is not achieved after the 2 rounds of the survey.

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Urologist from university hospitals in South Korea.
  • Has a minimum 10 years of practice experience (experience as a military or public health doctor could be considered practice experience)
  • Sees a minimum of 50 mHSPC patients in a year.
  • At least 10 publications in SCIE (Science Citation Index Expanded) journals in the past 5 years.

Exclusion criteria

  • Urologist in private practice.

Trial design

23 participants in 1 patient group

Urologists
Description:
Health care professionals/panelist.
Treatment:
Other: No Intervention

Trial contacts and locations

1

Loading...

Central trial contact

Astellas Pharma Korea, Inc.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems